Pre-market · Oct 6, 8:30 am ET · After hours $46.46 0.00%
Open$46.51
Prev close$46.90
Day range$45.81 – $47.35
Volume52.0K
Market cap$1.58B
P/E (TTM)9.5
Dividend yield6.52%
GLP Stock News
Headlines matching Global Partners or the GLP ticker, most recent first.
Accelerating global expansion! Hengrui Pharma licenses its oral GLP-1/GIP weight-loss drug to Novo-Nordisk A/S, with potential deal value reaching up to $2.6 billion.wallstreetcn · 29 Sep 2026
Hengrui Pharma Seals Up to US$2.6 Billion Global Licensing Deal With Novo Nordisk for Oral GLP-1/GIP DrugTipRanks · 29 Sep 2026
Will GLP-1s Hurt Food Stocks? Assessing the Changing Consumer.Yahoo Finance · 24 Sep 2026
Raymond James Initiates Global Partners(GLP.US) With Hold RatingMarket news · 11 Aug 2026
ASCLETIS-B: VOLUNTARY ANNOUNCEMENT - ASCLETIS ANNOUNCES INITIATION OF TWO PHASE I STUDIES INU.S. FOR THE TREATMENT OF OBESITY: ASC36 ONCE-MONTHLYINJECTION, AN AMYLIN RECEPTOR PEPTIDE AGONIST, ANDASC36_35FDC ONCE-MONTHLY INJECTION, A CO-FORMULATION OFASC36 AND GLP-1R/GHKEX · 10 Aug 2026
ASCLETIS-B: VOLUNTARY ANNOUNCEMENT - ASCLETIS SUBMITS TWO IND APPLICATIONS TO THE U.S. FDAFOR THE TREATMENT OF OBESITY: ASC36 ONCE-MONTHLYINJECTION, A PEPTIDE AMYLIN RECEPTOR AGONIST,AND ASC36_35 FDC ONCE-MONTHLY INJECTION,A CO-FORMULATION OF ASC36 PLUS PEPTIDE GLP-1RHKEX · 6 Jul 2026
ASCLETIS-B: VOLUNTARY ANNOUNCEMENT - ASCLETIS ANNOUNCES U.S. FDA IND CLEARANCE FOR PHASE I STUDYOF ONCE-MONTHLY SUBCUTANEOUSLY ADMINISTERED GLP-1R/GIPR DUAL PEPTIDE AGONIST, ASC35, FOR THE TREATMENT OF OBESITYHKEX · 23 Jun 2026
Yinuos (688710): Nantong Yinuos' "High-Quality Non-Clinical Innovative Drug Comprehensive Evaluation Platform Expansion Project" has obtained NMPA GLP certification.Northeast Securities · 11 Jun 2026
ASCLETIS-B: VOLUNTARY ANNOUNCEMENT - ASCLETIS COMPLETES ENROLLMENT IN U.S. PHASE II STUDY OFASC30, AN ORAL SMALL MOLECULE GLP-1R AGONIST, FOR THETREATMENT OF DIABETESHKEX · 27 Apr 2026
Jiaze Renewables Corporation: Jiaze New Energy Co., Ltd. Simplified Equity Change Report (Information Discloser: GLP Renewable Energy Investment I Limited)SZSI · 15 Apr 2026
Neutral Outlook on Magnum Ice Cream Co.: Soft Demand, Margin Pressure, and GLP-1 Risks Cap Near-Term UpsideTipRanks · 12 Feb 2026
Eli Lilly Scores FDA Win for Pancreatic Cancer Drug. How It's Moving Beyond GLP-1s. -- Barrons.comBarron's · 6 Oct 2026
From AI Infrastructure to GLP-1 Drugs, Here Are Investment Pros' Favorite Niche ETFs Now -- Barrons.comBarron's · 1 Oct 2026
TR | OpenAI - 4o Downgrades Global Partners(GLP.US) to Hold Rating, Cuts Target Price to $57Market news · 6 Aug 2025
Stifel Maintains Global Partners(GLP.US) With Hold Rating, Maintains Target Price $53Market news · 13 Aug 2025
Discussion
No comments yet — be the first to weigh in on GLP.
No comments yet — be the first to weigh in on GLP.